UTI Earnings

UTI reported its earnings on 2026-02-04, showcasing a revenue of 220.84M against an estimate of 217.21M, resulting in a 1.67% surprise. The EPS was 0.23, surpassing the expected 0.15 by 53.33%. The stock experienced a -11.16% price change on the earnings day and a -2.8% change over the next five days, reflecting market reactions to the results.

Following UTI's earnings announcement on 2026-02-04, the stock price moved by -11.16% on the day of the release. Over the subsequent five days, it saw a -2.8% change. Historically, UTI's stock price tends to shift by an average of -3.99% in the 10 days leading up to earnings and 3.48% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate UTI's annual revenue to reach 222.67M, while the EPS is projected at 0.07. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between UTI's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2026 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, UTI's stock price typically moves by -3.99% in the 10 days before its earnings and 3.48% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 0.07 and revenue of 222.67M.

The earnings call summary and Q&A indicate a positive outlook. The company is expanding with new campuses and programs, showing strong initial demand. Marketing investments are yielding positive results, and there is optimism about future growth. While margins are slightly pressured due to growth investments, this is not seen as a structural issue. CapEx plans are robust, supporting expansion, and there is strong interest in the Heartland model. Despite some lack of clarity on specific cohort sizes and partner initiatives, the overall sentiment is positive, supporting a prediction of a 2% to 8% stock price increase.